Legionella pneumophila Antibody (6021): sc-58164

Legionella pneumophila Antibody (6021) is a mouse monoclonal IgG1 antibody that detects Legionella pneumophila protein by immunofluorescence (IF). Anti-Legionella pneumophila antibody (6021) is available as a non-conjugated format. Legionella pneumophila is a gram-negative bacterium recognized as an intracellular pathogen, primarily responsible for Legionnaires′ disease, a severe form of pneumonia. The bacterium′s unique structure, particularly its lipopolysaccharide (LPS) content in the outer membrane, plays a crucial role in pathogenicity, contributing to evading host immune response and resisting certain antibiotics. This structural characteristic not only complicates staining in laboratory settings but also enhances virulence, allowing survival and replication within host cells. Infection typically occurs through inhalation of contaminated water droplets, leading to symptoms such as fever, chills, and dry cough, which can escalate to severe pneumonia that often resists standard treatments like penicillins and aminoglycosides. Legionnaires′ disease can affect multiple organ systems, including the gastrointestinal tract and central nervous system, underscoring the importance of early detection and intervention.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Legionella pneumophila Antibody (6021) References:

1. Legionella pneumophila suppresses interleukin-12 production by macrophages.  |  Matsunaga, K., et al. 2001. Infect Immun. 69: 1929-33. PMID: 11179377
2. Chromosomal insertion and excision of a 30 kb unstable genetic element is responsible for phase variation of lipopolysaccharide and other virulence determinants in Legionella pneumophila.  |  Lüneberg, E., et al. 2001. Mol Microbiol. 39: 1259-71. PMID: 11251842
3. Pathogenicity of Legionella pneumophila.  |  Cianciotto, NP. 2001. Int J Med Microbiol. 291: 331-43. PMID: 11727817
4. A point mutation in the active site of Legionella pneumophila O-acetyltransferase results in modified lipopolysaccharide but does not influence virulence.  |  Lück, PC., et al. 2001. Int J Med Microbiol. 291: 345-52. PMID: 11727818
5. Lipopolysaccharides from Legionella and Rhizobium stimulate mouse bone marrow granulocytes via Toll-like receptor 2.  |  Girard, R., et al. 2003. J Cell Sci. 116: 293-302. PMID: 12482915
6. Reduced interferon-gamma release in patients recovered from Legionnaires' disease.  |  Lettinga, KD., et al. 2003. Thorax. 58: 63-7. PMID: 12511724
7. A Rhizobium leguminosarum AcpXL mutant produces lipopolysaccharide lacking 27-hydroxyoctacosanoic acid.  |  Vedam, V., et al. 2003. J Bacteriol. 185: 1841-50. PMID: 12618448
8. Murein lipoprotein, peptidoglycan-associated lipoprotein, and outer membrane protein A are present in purified rough and smooth lipopolysaccharides.  |  Hellman, J., et al. 2003. J Infect Dis. 188: 286-9. PMID: 12854085
9. Epigallocatechin gallate modulates cytokine production by bone marrow-derived dendritic cells stimulated with lipopolysaccharide or muramyldipeptide, or infected with Legionella pneumophila.  |  Rogers, J., et al. 2005. Exp Biol Med (Maywood). 230: 645-51. PMID: 16179732